Tranzyme Pharma to Report First Quarter 2013 Financial Results

Tranzyme Pharma to Report First Quarter 2013 Financial Results

RESEARCH TRIANGLE PARK, N.C., May 2, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma
(Nasdaq:TZYM), today announced that the Company will report first quarter 2013
financial results after the close of the market on Thursday, May 9, 2013.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering,
developing and commercializing novel, mechanism-based therapeutics. All of
Tranzyme's drug discovery activities are based on its proprietary small
molecule macrocyclic template chemistry (MATCH™) technology, which has also
been successfully used to generate drug candidates in partnership with other
pharmaceutical companies. MATCH enables the rapid construct of synthetic
libraries of drug-like, macrocyclic compounds in a predictable and efficient
manner. By leveraging MATCH, Tranzyme is committed to pursuing first-in-class
medicines to address areas of significant unmet medical need and continues to
pursue funded drug discovery partnerships. Additional information on Tranzyme
can be found at www.tranzyme.com.

CONTACT: Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
 
Press spacebar to pause and continue. Press esc to stop.